Truffle’s portfolio company Carmat SAS, a French company that’s developing an artificial heart, successfully completed an IPO yesterday above its target.

The IPO will allow the company, founded in 2008, to complete pre-clinical trials on the artificial heart and start testing the device on humans. The implantable organ closely resembles a human heart, featuring right and left ventricles. The pump apparatus sits outside a membrane, isolated from any contact with the blood flow.

This represents the third IPO in as many months for Truffle’s Life Sciences team.

Including Truffle portfolio companies Neovacs and Deinove, Truffle Capital accounted for 3 out of the 8 IPOs in Europe this year .

A hearty congratulations to my colleagues !